share_log

Earnings Call Summary | Compugen(CGEN.US) Q1 2024 Earnings Conference

Earnings Call Summary | Compugen(CGEN.US) Q1 2024 Earnings Conference

業績電話會議摘要 | Compugen (CGEN.US) 2024 年第一季度業績會議
moomoo AI ·  05/20 18:04  · 電話會議

The following is a summary of the Compugen Ltd. (CGEN) Q1 2024 Earnings Call Transcript:

以下是Compugen有限公司(CGEN)2024年第一季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • Compugen reported a cash balance of approximately $101.3 million as of Q1 2024, including a $60 million upfront payment from Gilead and a $10 million milestone payment from AstraZeneca.

  • The company posted Q1 2024 revenue of $2.6 million.

  • R&D expenses and G&A expenses for Q1 2024 were $6.4 million and $2.4 million respectively, down from Q1 2023.

  • The reported net loss for Q1 2024 was $7.3 million or $0.08 per basic and diluted share.

  • Compugen報告稱,截至2024年第一季度,現金餘額約爲1.013億美元,其中包括吉利德的6000萬美元預付款和阿斯利康的1000萬美元里程碑式付款。

  • 該公司公佈的2024年第一季度收入爲260萬美元。

  • 2024年第一季度的研發費用和併購支出分別爲640萬美元和240萬美元,低於2023年第一季度。

  • 2024年第一季度報告的淨虧損爲730萬美元,合每股基本虧損和攤薄後虧損0.08美元。

Business Progress:

業務進展:

  • Compugen has made commendable advancements in their pipeline, with expectations for multiple readouts in 2024 including COM701, COM902, and a potential IND submission for COM503.

  • Compugen strategically partners with other companies, receiving upfront and milestone payments, and expecting more in the future.

  • The company prioritizes treatments for ovarian and colorectal cancers based on risk profiles and resource allocation, and is considering other indication strategies for endometrial, breast, and non-small cell lung cancers.

  • Compugen plans to share PVRL2 or biomarker data for future study enrichment plans, with a current focus on patients with high H scores of PVRL2.

  • Compugen在開發中取得了值得稱道的進展,預計將在2024年發佈多份讀數,包括COM701、COM902,以及可能提交的 COM503 的IND報告。

  • Compugen與其他公司進行戰略合作,獲得預付和里程碑式的付款,並期望未來會有更多付款。

  • 該公司根據風險狀況和資源分配優先考慮卵巢癌和結直腸癌的治療,並正在考慮子宮內膜癌、乳腺癌和非小細胞肺癌的其他適應症策略。

  • Compugen計劃爲未來的研究豐富計劃共享 PVRL2 或生物標誌物數據,目前的重點是 PVRL2 H 分數高的患者。

More details: Compugen IR

更多詳情: 康普根紅外

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論